B. Brockstein

NCCN Practice Guidelines for Head and Neck Cancers.

David G. Pfister, K.K. Ang, B. Brockstein et al. · PubMed · 2000 · 99 citations

Medicine, Cancer Diagnosis, Neck Pathology +8

Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors

B. Brockstein, Clayton M. Smiley, Jafar Al‐Sadir et al. · Bone Marrow Transplantation · 2000 · 79 citations

Cardiovascular Toxicity, Medicine, Breast Cancer +12

An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma

Mark Agulnik, Scott H. Okuno, Margaret von Mehren et al. · Journal of Clinical Oncology · 2009 · 46 citations

Oncology, Bevacizumab 15, New Therapies +11

A phase I–II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer

B. Brockstein, Daniel J. Haraf, Kerstin Stenson et al. · Annals of Oncology · 2000 · 44 citations

Poor Prognosis Head, Medicine, Factor Support +9

Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.

G. K. Schwartz, Robert G. Maki, Mark J. Ratain et al. · Journal of Clinical Oncology · 2011 · 21 citations

Subset Results, Prognostic Biomarkers, Phase Ii +13